IN8BIO INC. - COMMON

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

04 9 2024 13:01:00 提供 Nasdaq GlobeNewswire

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

29 8 2024 03:05:00 提供 Nasdaq GlobeNewswire

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

12 8 2024 05:05:00 提供 Nasdaq GlobeNewswire

IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

08 8 2024 13:05:00 提供 Nasdaq GlobeNewswire

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

24 6 2024 05:00:00 提供 Nasdaq GlobeNewswire

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

13 6 2024 13:01:00 提供 Nasdaq GlobeNewswire

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

03 6 2024 03:05:00 提供 Nasdaq GlobeNewswire

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

24 5 2024 05:00:00 提供 Nasdaq GlobeNewswire

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

23 5 2024 14:00:00 提供 Nasdaq GlobeNewswire

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

14 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

13 5 2024 05:00:00 提供 Nasdaq GlobeNewswire

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

09 5 2024 13:00:00 提供 Nasdaq GlobeNewswire

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

30 4 2024 03:05:00 提供 Nasdaq GlobeNewswire

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

24 4 2024 05:00:00 提供 Nasdaq GlobeNewswire

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

16 4 2024 13:05:00 提供 Nasdaq GlobeNewswire

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

09 4 2024 13:30:00 提供 Nasdaq GlobeNewswire

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

14 3 2024 13:00:00 提供 Nasdaq GlobeNewswire

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

05 3 2024 13:30:00 提供 Nasdaq GlobeNewswire

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

14 2 2024 05:00:00 提供 Nasdaq GlobeNewswire

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

04 1 2024 05:00:00 提供 Nasdaq GlobeNewswire